União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatite c, crônica - antivirais para uso sistêmico - viekirax é indicado em combinação com outros medicamentos para o tratamento de hepatite c crônica (chc) em adultos. para o vírus da hepatite c (vhc) genótipo específico de atividade.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocítica, crônica, células b - agentes antineoplásicos - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - o lopinavir, ritonavir - infecções por hiv - antivirals for systemic use, protease inhibitors - o kaletra é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento de adultos, adolescentes e crianças infectadas com vírus da imunodeficiência humana (hiv-1), com idade superior a 14 dias. a escolha do kaletra para tratar inibidor da protease experientes hiv-1 em pacientes infectados devem ser individuais de resistência vírica e tratamento histórico dos pacientes.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. - lopinavir, ritonavir - antiviroticos (inibe replicacao virotica)

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. - adalimumabe - antinflamatorios antireumaticos

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - infecções por hiv - antivirais para uso sistêmico - o ritonavir é indicado em combinação com outros agentes anti-retrovirais para o tratamento de pacientes infectados com hiv-1 (adultos e crianças de dois anos de idade e mais).

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

abbott laboratÓrios do brasil ltda - antiviroticos (inibe replicacao virotica)

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. - risanquizumabe - imunomodulador

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

abbvie, lda. - paricalcitol - solução injetável - 2 µg/ml - paricalcitol 2 µg/ml - paricalcitol - n/a - duração do tratamento: longa duração